| A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV (NCT07550504) | Samsung Bioepis Co., Ltd. | 2026-03-30 |
| A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors (NCT07524348) | Samsung Bioepis Co., Ltd. | 2026-03-23 |
| A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer (NCT06348199) | Samsung Bioepis Co., Ltd. | 2024-03-12 |
| A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy (NCT06268613) | Samsung Bioepis Co., Ltd. | 2024-01-16 |
| A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO (NCT06176963) | Samsung Bioepis Co., Ltd. | 2023-11-21 |
| Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT05510063) | Samsung Bioepis Co., Ltd. | 2022-08-04 |
| A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis (NCT04967508) | Samsung Bioepis Co., Ltd. | 2021-07-06 |
| A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects (NCT04772274) | Samsung Bioepis Co., Ltd. | 2021-02-04 |
| Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects (NCT04621318) | Samsung Bioepis Co., Ltd. | 2020-10-19 |
| Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects (NCT04514796) | Samsung Bioepis Co., Ltd. | 2020-08-13 |
| A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT04450329) | Samsung Bioepis Co., Ltd. | 2020-06-23 |
| A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria (NCT04058158) | Samsung Bioepis Co., Ltd. | 2019-08-07 |
| Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects (NCT03722329) | Samsung Bioepis Co., Ltd. | 2018-11-13 |
| A Phase I Study of SB26 in Healthy Volunteers (NCT03630627) | Samsung Bioepis Co., Ltd. | 2018-08-22 |
| A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT03150589) | Samsung Bioepis Co., Ltd. | 2018-03-14 |